A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
Latest Information Update: 25 Jul 2022
At a glance
- Drugs Avizakimab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boston Pharmaceuticals
- 23 Nov 2020 Status changed from active, no longer recruiting to completed.
- 25 Aug 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Nov 2020.
- 16 Apr 2020 Status changed from recruiting to active, no longer recruiting.